11/18
05:59 pm
auph
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis [Yahoo! Finance]
Low
Report
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis [Yahoo! Finance]
11/18
05:53 pm
auph
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
Low
Report
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
11/15
06:00 am
auph
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
Low
Report
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
11/14
06:15 am
auph
Aurinia to Participate in Jefferies London Healthcare Conference [Yahoo! Finance]
Low
Report
Aurinia to Participate in Jefferies London Healthcare Conference [Yahoo! Finance]
11/14
06:00 am
auph
Aurinia to Participate in Jefferies London Healthcare Conference
Low
Report
Aurinia to Participate in Jefferies London Healthcare Conference
11/8
11:07 pm
auph
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Low
Report
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
11/8
02:21 am
auph
Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... [Yahoo! Finance]
Low
Report
Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... [Yahoo! Finance]
11/7
06:10 am
auph
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
Low
Report
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
11/7
06:00 am
auph
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development
Medium
Report
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development
11/2
10:59 am
auph
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) are in the red if they invested three years ago [Yahoo! Finance]
Low
Report
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) are in the red if they invested three years ago [Yahoo! Finance]
10/30
04:05 pm
auph
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
Low
Report
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
10/30
06:00 am
auph
Axonis Therapeutics Announces $115 Million Series A Financing
Low
Report
Axonis Therapeutics Announces $115 Million Series A Financing
10/11
06:00 am
auph
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
Low
Report
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
9/27
09:23 am
auph
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability [Yahoo! Finance]
Low
Report
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability [Yahoo! Finance]
9/24
08:10 am
auph
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
Low
Report
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
9/19
08:21 am
auph
Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment [Seeking Alpha]
Low
Report
Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment [Seeking Alpha]
9/18
04:59 am
auph
Aurinia Pharmaceuticals: This Recovery Can Continue [Seeking Alpha]
Low
Report
Aurinia Pharmaceuticals: This Recovery Can Continue [Seeking Alpha]
9/16
12:11 pm
auph
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $10.00 price target on the stock.
Low
Report
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $10.00 price target on the stock.
9/13
06:00 am
auph
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
Low
Report
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
9/12
04:05 pm
auph
Aurinia Announces Board Restructuring
Medium
Report
Aurinia Announces Board Restructuring
9/9
12:14 pm
auph
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $10.00 price target on the stock.
Low
Report
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $10.00 price target on the stock.
9/6
08:08 am
auph
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.
Medium
Report
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.
9/6
07:37 am
auph
Aurinia doses first subject in Phase Ia trial of AUR200 for autoimmune diseases [Yahoo! Finance]
Medium
Report
Aurinia doses first subject in Phase Ia trial of AUR200 for autoimmune diseases [Yahoo! Finance]
9/5
06:00 am
auph
Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
Low
Report
Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
8/28
06:00 am
auph
Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Low
Report
Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference